{"id":"W2053290453","doi":"10.1158/1078-0432.ccr-07-0835","title":"Synergistic Interactions between Vorinostat and Sorafenib in Chronic Myelogenous Leukemia Cells Involve Mcl-1 and p21CIP1 Down-Regulation","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":65,"is_retracted":true,"has_abstract":true,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; National Institutes of Health; Leukemia and Lymphoma Society; U.S. Department of Defense","keywords":"Vorinostat; Imatinib mesylate; Sorafenib; Cancer research; Chronic myelogenous leukemia; Histone deacetylase inhibitor; Imatinib; Histone deacetylase; Pharmacology; Biology; Chemistry; Leukemia; Myeloid leukemia; Immunology; Histone; Biochemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":{"nature":"Retraction","reason":"Falsification/Fabrication of Data;Falsification/Fabrication of Image;Investigation by ORI;Misconduct by Author;","date":"10/1/2016 0:00","openalex_flagged":true},"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000161193,0.000463559,0.0005368328,0.0002453374,0.0002025771,0.0003343121,0.0001772332,0.0002281955,0.00189619],"category_scores_gemma":[0.0001421106,0.0001365092,0.0004013371,0.000183447,0.0001919275,0.0002367537,0.0002366353,0.0003699317,0.0004289937],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002862476,"about_ca_system_score_gemma":0.0002230924,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001858052,"about_ca_topic_score_gemma":0.0006985075,"domain_scores_codex":[0.9997856,0.00004657395,0.0000191064,0.00003587935,0.00006234578,0.00005052938],"domain_scores_gemma":[0.9999168,0.00001996186,0.00002491421,0.000009547692,0.000008816716,0.00001990566],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0006449402,0.0001444362,0.0005221861,0.0001078853,0.00002289479,0.0001195536,0.00001975187,0.0001336419,0.994165,0.00006992622,0.0001290775,0.003920712],"study_design_scores_gemma":[0.0001610885,0.002434867,0.01798593,0.000008585077,0.00007999848,0.000818615,0.0000581441,0.001541756,0.9721106,0.00007174321,0.004719967,0.00000878399],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9935684,0.003612696,0.0008378528,0.0001186904,0.00004460563,0.00004852749,0.0002652893,0.00006073902,0.001443127],"genre_scores_gemma":[0.9975063,0.0008461871,0.0005385411,0.00003072756,0.00001869364,0.0000435364,0.0002856929,0.000004479914,0.0007260064],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00189619,"threshold_uncertainty_score":0.006343424,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1819848224236344,"score_gpt":0.5002775618152996,"score_spread":0.3182927393916652,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}